The U.S. Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded Arizona State University a $1,103,084 Project Grant to develop a personalized blood-based diagnostic assay for the early detection of amyotrophic lateral sclerosis (ALS). The performance period for this award is from November 1, 2024 to October 31, 2026.
As a sub-award under this grant, Georgetown University received funding to contribute its expertise in this project. The objective is to develop an innovative, blood-based diagnostic tool that can enable earlier and more personalized detection of ALS, a debilitating neurological disorder that significantly impacts military service members and veterans. The federal funding supports advanced scientific research aimed at improving health outcomes for the military community and the general public.
Generated 3/4/25, 7:53 AM